The December issue of Pharmafocus is available to read online now!
pharmafile | December 12, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharmaÂ
The December edition of Pharmafocus is live and available to read online now!
Brexit continues to dominate the headlines inside and outside the industry, but for our final issue of 2018, we have a slew of content and news to round out the year.
Among them, Mesothelioma.net provides an insight into the latest challenges and advancements in tackling the deadly cancer, and we have a full-length feature on how the latest technological innovations such as artificial intelligence are helping to galvanise our approaches to precision medicine, whether that is informing the earliest stages of drug discovery or calculating the optimum dosage to deliver to patients.
To celebrate the end of another year, we also have an annual round-up feature including commentary from Gilead, Mundipharma, Eisai and more, each discussing their key moments of 2018, insight on developing trends, and their predictions for next year.
And in our monthly Working Life, we speak to Kai Gait, GSK’s Senior Global Digital Director, on his path through the industry; he recalls the bloom of his love of tech, and discusses its ever-growing importance in the industry.
You can find this and much more in our December issue. We also recently released our Autumn edition of Pharmafile, our bi-annual therapeutic focus for pharma and life sciences, which you can read online here.
From us at Pharmafocus, have a great holiday period and New Year, and we’ll see you in 2019 to bring you all the latest in the industry as it happens.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
